NCT06914141Completed
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Source: ClinicalTrials.gov · Last updated 30 Jan 2026
Brief summary (registry, in English)
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 28118 (actual)
- First submitted
- 31 Mar 2025
- Start date
- 14 Jan 2025
- Primary completion date
- 1 Jun 2025
- Lead sponsor
- Brigham and Women's Hospital
- Diseases
- Heart failure, Type 2 diabetes
- NCT number
- NCT06914141
What you commit to
- Study type: Observational
- Participants enrolled: 28118
- From 14 Jan 2025 to the primary completion date, 1 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with any GLP-1-RA
- Treatment with continuous subcutaneous insulin infusion
Other illness
- History of type 1 diabetes mellitus
- End-stage renal disease or chronic or intermittent haemodialysis or peritoneal dialysis
- History of bariatric surgery
- History of nursing home admission
- Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinoma of the cervix, or in situ prostate cancer) for less than 5 years
Other
- Pregnant female or breastfeeding
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy
- Multiple endocrine neoplasia type 2 or medullary thyroid carcinoma
Who the study is looking for
- Heart failure
- BMI \> 27.0 kg/m2
- History of type 2 diabetes mellitus
- LVEF ≥ 45%
- ≥ 18 years old, male or female sex
Criteria the registry did not label
- Eligible cohort entry dates:
- Optum: Study period between May 13, 2022 to November 30, 2024. Marketscan: Study period between May 13, 2022 to December 31, 2023.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Brigham and Women's Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.